Inc. in October 2007 and $(552,900)K related to our acquisition of
AnorMED Inc. in November 2006.
(6) Represents the write off of the goodwill related to our Genetics
reporting unit in September 2006 in accordance with FAS 142,
"Goodwill and Other Intangible Assets."
(7) Includes charges of $(570)K for the three months ended and $(21,102)K
for the year ended December 31, 2007 related to our completion of the
first step of the two step process under which we acquired
Bioenvision. In July 2007, we acquired approximately 22% of the
outstanding shares of Bioenvision common stock on an as-converted
basis, including all of the outstanding shares of Bioenvision
preferred stock for $(72,229)K of cash. Subsequently, in October
2007, following a favorable merger vote by Bioenvision's
shareholders, we completed the second step of the acquisition and,
effective October 23, 2007, acquired the remaining outstanding shares
of Bioenvision common stock for $(245,055)K of cash. In the fourth
quarter of 2007, we also paid $(11,975)K of cash for the outstanding
options to purchase shares of Bioenvision common stock. The full
purchase accounting for the acquisition of Bioenvision, including the
impact of the second step, is reflected in our consolidated financial
statements for the three months and year ended December 31, 2007 and
as of December 31, 2007.
(8) For the year ended December 31, 2007, includes a pre-tax gain of
$10,848K recorded on the sale of our entire investment in the common
stock of Therapeutic Human Polyclonals Inc. in March 2007, which had
a zero cost basis. For the year ended December 31, 2006, includes
pre- tax gains of $69,359K related to the liquidation
|SOURCE Genzyme Corporation|
Copyright©2008 PR Newswire.
All rights reserved